Posts

FDA to Review Reclassifying Peptides Following RFK Jr.'s Push Ahead of July Advisory Meeting

The FDA announced on April 15, 2026, a July meeting to consider easing restrictions on seven peptides, including BPC-157 and TB-500, potentially moving them from Category 2 (restricted) to Category 1 for compounding by pharmacies. 1 5 This follows RFK Jr.'s February 2026 statements calling the prior FDA restrictions on 14-19 peptides 'illegal' and pledging to loosen regulations. 1 2 3 Peptides were placed in Category 2 in 2023 under Biden due to safety risks like cancer, organ damage, and lack of human testing data; they remain unapproved drugs. 1 2 4 Influencers promote peptides for muscle building, injury healing, and anti-aging, but they lack FDA safety review and are banned in sports as doping agents. 1 4 Reclassification would allow licensed pharmacies to produce them under prescription but does not approve them as drugs. 2 4 Sources: 1. https://abcnews.com/US/wireStory/fda-weigh-easing-limits-unproven-peptides-favored-rfk-132059441 2. https://skytalegrou...

Novartis CEO Vas Narasimhan Joins Anthropic Board to Advance Responsible AI in Healthcare

Terremoto Raises $108M to Make an 'Earthquake' in Small Molecule Space

NeuraClick Expands Scientific and Translational Leadership with Key Advisory Appointments

Pivotal Pancreatic Cancer Data Fuels Revolution Medicines' Upsized $2B Offering

Beeline Biotech Launches with $300M Funding and Bristol Myers Squibb-Derived Pipeline

Magnetic Seizure Therapy Shows Efficacy and Safety Comparable to Electroconvulsive Therapy for Depression

Mike Sciandra's Journey from Gambling Addiction to Recovery and Advocacy

2026 AAPS National Biotechnology Conference: Plenary Speakers and Key Details Announced

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS Cancer Drugs as Biotech Sector Heats Up

Bristol Myers Squibb and Bain Capital Launch New Autoimmune Disease Biotech Company

Biogen's $5.6B Apellis Acquisition: Key Biotech Deals Including Telix's $600M Raise and Obsidian's IPO Plans

Spotlight On: Tackling Core Challenges in Drug R&D with AI